Skip to main content
Top
Published in: Infectious Diseases and Therapy 1/2021

Open Access 01-03-2021 | Hepatitis B | Original Research

Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study

Authors: Yu-Xia Lu, Cheng-Zhi He, Ying-Xin Wang, Zi-Sheng Ai, Ping Liang, Chang-Qing Yang

Published in: Infectious Diseases and Therapy | Issue 1/2021

Login to get access

Abstract

Introduction

This study aimed to analyze the diversity of intestinal flora in patients with chronic hepatitis B (CHB) and investigate the effect of entecavir on the intestinal flora in these patients.

Methods

Thirty patients with CHB and 30 healthy controls were recruited from the Department of Infectious Diseases and Department of Gastroenterology of Shanghai Tongji Hospital between January 2017 and December 2018. Stool samples were collected for the detection of intestinal flora by high-throughput sequencing. Patients with CHB received antivirus therapy with entecavir for 8 weeks. The biochemical and virological responses were assessed and the intestinal flora were compared.

Results

After entecavir treatment, the blood levels of alanine aminotransferase (ALT), interleukin-6 (IL-6), IL-8, tumor necrosis factor (TNF), and hepatitis B virus (HBV) DNA reduced significantly in patients with CHB and the species abundance of intestinal flora increased markedly. In patients with CHB, the unique genera included Butyrivibrio, Phaseolus acutifolius, and Prevotellaceae NK3B31 group before treatment and Howardella, Candidatus Stoquefichus, Citrobacter, Dysgonomonas, Faecalicoccus, Methanobrevibacter, Mitsuokella, Mobilitalea, Succinivibrio, Gluconobacter, and Plesiomonas after treatment. The abundance of the following genera increased significantly after entecavir treatment in patients with CHB: Clostridium sensu stricto 1, Erysipelotrichaceae UCG-007, and Intestinibacter. The abundance of Streptococcus, Atopobium, and Murdochiella reduced markedly after entecavir treatment in patients with CHB.

Conclusion

After 8-week entecavir treatment, the blood biochemical, immunological, and virological responses improved significantly, the species abundance of intestinal flora increased markedly, and there were unique genera in patients with CHB before and after treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Razavi-Shearer D, Gamkrelidze I, Nguyen MH, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383–403.CrossRef Razavi-Shearer D, Gamkrelidze I, Nguyen MH, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383–403.CrossRef
2.
go back to reference Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–9.CrossRef Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–9.CrossRef
3.
go back to reference Hou J, Wang G, Wang F, et al. Guideline of prevention and treatment for chronic hepatitis B (2015 update). J Clin Transl Hepatol. 2017;5:297–318.CrossRef Hou J, Wang G, Wang F, et al. Guideline of prevention and treatment for chronic hepatitis B (2015 update). J Clin Transl Hepatol. 2017;5:297–318.CrossRef
4.
go back to reference Marshall JC. The gut as a potential trigger of exercise-induced inflammatory responses. Can J Physiol Pharmacol. 1998;76:479–84.CrossRef Marshall JC. The gut as a potential trigger of exercise-induced inflammatory responses. Can J Physiol Pharmacol. 1998;76:479–84.CrossRef
5.
go back to reference Fu ZD, Cui JY. Remote sensing between liver and intestine: importance of microbial metabolites. Curr Pharmacol Rep. 2017;3:101–13.CrossRef Fu ZD, Cui JY. Remote sensing between liver and intestine: importance of microbial metabolites. Curr Pharmacol Rep. 2017;3:101–13.CrossRef
6.
go back to reference Koh JC, Loo WM, Goh KL, et al. Asian consensus on the relationship between obesity and gastrointestinal and liver diseases. J Gastroenterol Hepatol. 2016;31:1405–13.CrossRef Koh JC, Loo WM, Goh KL, et al. Asian consensus on the relationship between obesity and gastrointestinal and liver diseases. J Gastroenterol Hepatol. 2016;31:1405–13.CrossRef
7.
go back to reference Lu H, Wu Z, Xu W, Yang J, Chen Y, Li L. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microb Ecol. 2011;61:693–703.CrossRef Lu H, Wu Z, Xu W, Yang J, Chen Y, Li L. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microb Ecol. 2011;61:693–703.CrossRef
8.
go back to reference Xing HC. Host factors influencing the clinical outcome of chronic hepatitis B virus infection. Zhonghua Gan Zang Bing Za Zhi = Chin J Hepatol. 2017;25:495–9. Xing HC. Host factors influencing the clinical outcome of chronic hepatitis B virus infection. Zhonghua Gan Zang Bing Za Zhi = Chin J Hepatol. 2017;25:495–9.
9.
go back to reference Xu D, Huang Y, Wang J. Gut microbiota modulate the immune effect against hepatitis B virus infection. Eur J Clin Microbiol Infect Dis. 2015;34:2139–47.CrossRef Xu D, Huang Y, Wang J. Gut microbiota modulate the immune effect against hepatitis B virus infection. Eur J Clin Microbiol Infect Dis. 2015;34:2139–47.CrossRef
10.
go back to reference Derovs A, Laivacuma S, Krumina A. Targeting microbiota: what do we know about it at present? Medicina (Kaunas). 2019;55:459.CrossRef Derovs A, Laivacuma S, Krumina A. Targeting microbiota: what do we know about it at present? Medicina (Kaunas). 2019;55:459.CrossRef
11.
go back to reference Milosevic I, Vujovic A, Barac A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature. Int J Mol Sci. 2019;20:395.CrossRef Milosevic I, Vujovic A, Barac A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature. Int J Mol Sci. 2019;20:395.CrossRef
12.
go back to reference Yang R, Xu Y, Dai Z, Lin X, Wang H. The immunologic role of gut microbiota in patients with chronic HBV infection. J Immunol Res. 2018;2018:2361963.PubMedPubMedCentral Yang R, Xu Y, Dai Z, Lin X, Wang H. The immunologic role of gut microbiota in patients with chronic HBV infection. J Immunol Res. 2018;2018:2361963.PubMedPubMedCentral
13.
go back to reference Tsai KN, Kuo CF, Ou JJ. Mechanisms of hepatitis B virus persistence. Trends Microbiol. 2018;26:33–42.CrossRef Tsai KN, Kuo CF, Ou JJ. Mechanisms of hepatitis B virus persistence. Trends Microbiol. 2018;26:33–42.CrossRef
14.
go back to reference Schwenger KJ, Clermont-Dejean N, Allard JP. The role of the gut microbiome in chronic liver disease: the clinical evidence revised. JHEP Rep. 2019;1:214–26.CrossRef Schwenger KJ, Clermont-Dejean N, Allard JP. The role of the gut microbiome in chronic liver disease: the clinical evidence revised. JHEP Rep. 2019;1:214–26.CrossRef
15.
go back to reference Woodhouse CA, Patel VC, Singanayagam A, Shawcross DL. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 2018;47:192–202.CrossRef Woodhouse CA, Patel VC, Singanayagam A, Shawcross DL. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 2018;47:192–202.CrossRef
16.
go back to reference Manne V, Gochanour E, Kowdley KV. Current perspectives into the evaluation and management of hepatitis B: a review. Hepatobiliary Surg Nutr. 2019;8:361–9.CrossRef Manne V, Gochanour E, Kowdley KV. Current perspectives into the evaluation and management of hepatitis B: a review. Hepatobiliary Surg Nutr. 2019;8:361–9.CrossRef
17.
go back to reference Mak LY, Seto WK, Fung J, Yuen MF. New biomarkers of chronic hepatitis B. Gut Liver. 2019;13:589–95.CrossRef Mak LY, Seto WK, Fung J, Yuen MF. New biomarkers of chronic hepatitis B. Gut Liver. 2019;13:589–95.CrossRef
18.
go back to reference Wang HW, Lai HC, Hu TH, et al. On-treatment changes in FIB-4 and 1-year FIB-4 values help identify patients with chronic hepatitis B receiving entecavir therapy who have the lowest risk of hepatocellular carcinoma. Cancers (Basel). 2020;12:1177.CrossRef Wang HW, Lai HC, Hu TH, et al. On-treatment changes in FIB-4 and 1-year FIB-4 values help identify patients with chronic hepatitis B receiving entecavir therapy who have the lowest risk of hepatocellular carcinoma. Cancers (Basel). 2020;12:1177.CrossRef
19.
go back to reference Cho JY, Sohn W, Paik YH, et al. Long-term hepatitis B surface antigen (HBsAg) kinetics during entecavir treatment in Korean patients—functional cure unlikely. J Viral Hepat. 2020;27(9):951–4. Cho JY, Sohn W, Paik YH, et al. Long-term hepatitis B surface antigen (HBsAg) kinetics during entecavir treatment in Korean patients—functional cure unlikely. J Viral Hepat. 2020;27(9):951–4.
20.
go back to reference Geng J, Bao H, Chen Y, et al. Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis. Expert Rev Anti Infect Ther. 2020;18(8):823–34. Geng J, Bao H, Chen Y, et al. Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis. Expert Rev Anti Infect Ther. 2020;18(8):823–34.
21.
go back to reference Wani MA, Sodhi JS, Zargar SA, et al. Entecavir is safe and effective in long term for the treatment of hepatitis B in immunocompromised children. J Clin Exp Hepatol. 2020;10:150–4.CrossRef Wani MA, Sodhi JS, Zargar SA, et al. Entecavir is safe and effective in long term for the treatment of hepatitis B in immunocompromised children. J Clin Exp Hepatol. 2020;10:150–4.CrossRef
22.
go back to reference Li X, Wu S, Du Y, Yang L, Li Y, Hong B. Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model. Int J Antimicrob Agents. 2020;56:106000.CrossRef Li X, Wu S, Du Y, Yang L, Li Y, Hong B. Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model. Int J Antimicrob Agents. 2020;56:106000.CrossRef
Metadata
Title
Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study
Authors
Yu-Xia Lu
Cheng-Zhi He
Ying-Xin Wang
Zi-Sheng Ai
Ping Liang
Chang-Qing Yang
Publication date
01-03-2021
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 1/2021
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-020-00355-w

Other articles of this Issue 1/2021

Infectious Diseases and Therapy 1/2021 Go to the issue